# Alzheimer's Breakthrough: Precision Treatments on the Rise!

Newsy: Alzheimer’s News Weekly
Published: 2025-12-15T14:46:00.543Z
Source: https://newsyai.com/edition/8330f793-eadc-4ca5-b6b6-742bf07f7b85
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

# Alzheimer’s Treatment Briefing
Coverage period: December 9–15, 2025 (U.S.)

Below are the most meaningful, truly new developments from the past seven days that affect how we treat — or soon might treat — Alzheimer’s disease.

## Top stories (ranked)

1) The field pivots toward combination and “precision” treatment strategies
- Overview
  - A new report this week highlights a clear shift: researchers and drugmakers are moving away from one‑target drugs and toward combination approaches (for example, pairing anti‑amyloid with anti‑tau or anti‑inflammation) and more personalized care, matching therapies to a person’s biology. Leaders in the field liken it to how cancer care evolved: earlier treatment, smarter diagnostics (especially blood tests), and combinations to cover more than one disease process. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/alzheimers-drug-hunt-learns-cancer-fights-multi-target-playbook-2025-12-12/?utm_source=openai))
- Why this matters
  - Expect more trials that add a second drug to lecanemab or donanemab, and more use of blood tests to pick who’s most likely to benefit. If you’re treating patients now, plan for a future where “one size fits all” gives way to “right drug(s) for the right patient.”

2) Agitation in Alzheimer’s: mid‑stage trial hits a key enrollment milestone
- Overview
  - IGC Pharma said its Phase 2 trial (CALMA) of IGC‑AD1 for agitation in Alzheimer’s is 65% enrolled, aiming to finish enrollment in early 2026. Agitation is one of the most challenging and stressful symptoms for families and care teams, with limited safe options today. While this study doesn’t target the root disease, it addresses a major care gap. ([investor.igcpharma.com](https://investor.igcpharma.com/igc-pharma-reports-65-patient-enrollment-milestone-in-phase-2-calma-alzheimers-agitation-trial/?utm_source=openai))
- Why this matters
  - Better treatments for agitation could reduce ER visits, caregiver burnout, and the need for sedating drugs. Keep an eye on this and similar trials as part of a more complete care toolbox alongside disease‑slowing antibodies.

3) What this week’s trend means for anti‑tau and other add‑on therapies
- Overview
  - The “combination” push reinforces ongoing programs that add anti‑tau drugs to amyloid‑clearing treatment (for example, etalanetug added to lecanemab in DIAN‑TU, and other anti‑tau antibodies in Phase 2). The message this week: slowing amyloid is helpful, but tackling tau and inflammation may be needed to sustain or deepen benefit. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/alzheimers-drug-hunt-learns-cancer-fights-multi-target-playbook-2025-12-12/?utm_source=openai))
- Why this matters
  - If you’re counseling patients and families, set expectations that second‑wave add‑on therapies (anti‑tau, anti‑inflammation) are being tested now and could be layered onto today’s drugs in the coming years, pending results.

---

## What this means for care right now
- Keep using simple blood tests to triage: They will matter even more as trials and future care pathways sort patients by biology for the best fit therapy or combinations. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/alzheimers-drug-hunt-learns-cancer-fights-multi-target-playbook-2025-12-12/?utm_source=openai))
- Watch for combination‑therapy trials patients can join: This week’s industry signals point to more add‑on studies (anti‑tau, anti‑inflammation) on top of lecanemab/donanemab. Discuss trial options early for motivated patients. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/alzheimers-drug-hunt-learns-cancer-fights-multi-target-playbook-2025-12-12/?utm_source=openai))
- Don’t overlook symptom control: New disease‑slowing drugs don’t fix agitation or sleep problems. Mid‑stage agitation trials are moving, and results over the next year could add safe, targeted options to reduce crises at home and in facilities. ([investor.igcpharma.com](https://investor.igcpharma.com/igc-pharma-reports-65-patient-enrollment-milestone-in-phase-2-calma-alzheimers-agitation-trial/?utm_source=openai))

If you’d like, I can flag the first combination‑therapy readouts as soon as they drop and summarize whether they’re ready to change practice.
